Palisade Bio (PALI) Non-Current Assets (2010 - 2026)
Palisade Bio (PALI) reported Non-Current Assets of $72000.0 for Q1 2026, down 76.24% year-over-year from $303000.0 in Q1 2025, and down 41.46% quarter-over-quarter from $123000.0 in Q4 2025.
Palisade Bio (PALI) Non-Current Assets (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has 17 years of Non-Current Assets data on file, last reported at $72000.0 in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $72000.0, down 76.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $560000.0 (down 67.33% YoY), and the FY2025 annual result was $123000.0, down 68.13% from the prior year.
- Non-Current Assets fell to $72000.0 in Q1 2026 per PALI's latest filing, from $123000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.1 million in Q3 2022 and troughed at $72000.0 in Q1 2026.
- A 5-year average of $523000.0 and a median of $466000.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets soared 935.87% in 2023, then slumped 76.24% in 2026.
- A 5-year view of Non-Current Assets shows it stood at $1.0 million in 2022, then retreated by 29.71% to $724000.0 in 2023, then plunged by 46.69% to $386000.0 in 2024, then plunged by 68.13% to $123000.0 in 2025, then plunged by 41.46% to $72000.0 in 2026.
- Business Quant data shows PALI's Non-Current Assets at $72000.0 in Q1 2026, $123000.0 in Q4 2025, and $145000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Palisade Bio | 391.02 Mn | 261.45 Mn | - | 72,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | 145,000.00 |
| Jun 30, 2025 | 220,000.00 |
| Mar 31, 2025 | 303,000.00 |
| Dec 31, 2024 | 386,000.00 |
| Sep 30, 2024 | 466,000.00 |
| Jun 30, 2024 | 559,000.00 |
| Mar 31, 2024 | 639,000.00 |
| Dec 31, 2023 | 724,000.00 |
| Sep 30, 2023 | 801,000.00 |
| Jun 30, 2023 | 879,000.00 |
| Mar 31, 2023 | 953,000.00 |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 391,000.00 |
| Mar 31, 2022 | 92,000.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 182,000.00 |
| Jun 30, 2021 | 224,000.00 |